Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Breast 2Thoracic 1Other neoplasm 1Gastrointestinal 1

Conditions

Uterine Neoplasms 1Ovarian Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Leiomyoma 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Bupivacaine × Gynecologic × Clear all
NCT04849858 2024-08-23

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

University of California, Irvine

Phase 3 Terminated
13 enrolled
Gynecologic

Leiomyoma, Ovarian Neoplasms, Uterine Neoplasms

NCT02740114 2021-10-18

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

M.D. Anderson Cancer Center

Phase 3 Terminated
105 enrolled 9 charts
GynecologicOther neoplasm

Malignant Neoplasms of Female Genital Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡